retatrutide phase 2 obesity trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide trial results in 28

These findings are investigational

[DOI] [PMC free article] [PubMed] [Google Scholar] 49.Vos M.B., Abrams S.H., Barlow S.E., et al

This process helps regulate insulin and glucagon levels, reduce appetite, slow gastric emptying, and promote a feeling of fullness after mealsmaking it easier to manage portions and reduce overall calorie intake

Hillis GS, Woodward M, Rodgers A, Chow CK, Li Q, Zoungas S, Patel A, Webster R, Batty GD, Ninomiya T, Mancia G, Poulter NR, Chalmers J

Retatrutide (GLP-1/GIP/Glucagon Triple Agonist) The development of retatrutide represents a major breakthrough because it now targets the glucagon receptor alongside GLP-1 and GIP receptors

This gives the dermis a head start on collagen production before significant volume loss has occurred